Sebastian Szmit/LinkedIn
Jul 2, 2025, 08:14
Sebastian Szmit: Phase 2 Trial with Dapagliflozin in Patients with Newly Diagnosed MM Undergoing Auto-HSCT
Sebastian Szmit, Chair of the Council of Cardio-Oncology Study Group on Thrombosis at the European Society of Cardiology, shared a post on LinkedIn:
“Great Achievement!
Agencja Badań Medycznych will support our study entitled
A Randomized, Double‐Blind, Phase 2 Trial Evaluating the Efficacy, Safety, and Tolerability of Primary Cardioprotection with Dapagliflozin in Patients with Newly Diagnosed Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation (HEART‐DAPA‐ MM)
Congratulations to the Leaders.”
More posts featuring Sebastian Szmit.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jul 20, 2025, 20:20
Jul 20, 2025, 20:10
Jul 20, 2025, 19:54
Jul 20, 2025, 19:20
Jul 20, 2025, 18:59
Jul 20, 2025, 18:27
Jul 20, 2025, 18:12
Jul 20, 2025, 17:37